A Review on Novel Biochemical Mediator Triggered on Demand Drug Delivery System

Mithila Sawalwade, Anup Naha, Shubham Zende

Abstract

Unavailability of drug in appropriate amounts on apt time at the desired site of action can lead to further complications in the diseases which can turn into more deadly condition. Timely delivery of right amount of drug is very crucial in proper therapy, thereby avoiding the adverse effects of the drug. Feedback regulated closed loop delivery system can controllably deliver the drug on demand which means the release rates can be increased, decreased or totally stopped, as a response towards physiochemical response produced by the body. The system can be designed in such a way that the concentration of the drug released from the system is proportional to the degree of stimuli produced by the body. Various diseases and disorders progress by feedback loop mechanisms, owing to which biochemical signal triggered delivery of drug can be achieved in such conditions. The system is also advantageous in case of some drugs whose fluctuation in plasma concentrations is unenviable. In the current work, self-regulated drug delivery devices designed for various conditions like diabetes mellitus, hypercoagulation, cancer, microbial infections and opioid poisoning are reviewed. Various combinations of smart polymers are employed to design such devices that work by responding to the feedback produced by the body.

Full Text:

PDF

References

Satav SS, Bhat S, Thayumanavan S. Feedback regulated drug delivery vehicles: carbon dioxide responsive cationic hydrogels for antidote release. Biomacromolecules. 2010 Jul 12;11(7):1735-40.

Wanakule P, Roy K. Disease-responsive drug delivery: the next generation of smart delivery devices. Current drug metabolism. 2012 Jan 1;13(1):42-9.

Chien YW. Concepts and system design for rate-controlled drug delivery, in: Y.W. Chien (Ed.), Novel Drug Delivery Systems, Marcel Decker, Inc; New York. 1992: pp 33–36.

Schwartz SS, Jellinger PS, Herman ME. Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile. Postgraduate medicine. 2016 Aug 17;128(6):609-19.

Rupashri SV, Gheena S. Recent advances in diabetes research. Research Journal of Pharmacy and Technology. 2016;9(10):1806-8.

Type 1 Diabetes Statistics [Internet]. Beyond Type 1. [cited 2019 Jun 18]. Available from: https://beyondtype1.org/type-1-diabetes-statistics/

Shah RB et al. Insulin delivery methods: past, present and future. International journal of pharmaceutical investigation. 2016 Jan;6(1):1.

Chantelau E et al. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia. 1989 Jul 1;32(7):421-6.

Matthews DR et al. Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes. 1983 Jul 1;32(7):617-21.

Okamura S et al. Localized amyloidosis at the site of repeated insulin injection in a patient with type 2 diabetes. Diabetes Care. 2013 Dec 1;36(12):e200-.

Nagase T et al. The insulin ball. The Lancet. 2009 Jan 10;373(9658):184.

Chin RL et al. Gas gangrene from subcutaneous insulin administration. The American journal of emergency medicine. 1993 Nov 1;11(6):622-5.

RAAB AP, RABINOWITZ MA. Glycosuria and hyperglycemia in coronary thrombosis. Journal of the American Medical Association. 1936 May 16;106(20):1705-8.

LAPIDOTH T, GALUN E. Hyperglycemia as a cause of chorea. Archives of internal medicine. 1989 Aug 1;149(8):1905-.

Herrick WW. Hypertension and hyperglycemia. Journal of the American Medical Association. 1923 Dec 8;81(23):1942-4.

Kamtekar S, Keer V. Management of Diabetes: A Review. Research Journal of Pharmacy and Technology. 2014;7(9):1065-72.

Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes. 1994 Feb 1;43(2):313-7.

Clarke WL et al. Reduced awareness of hypoglycemia in adults with IDDM: a prospective study of hypoglycemic frequency and associated symptoms. Diabetes care. 1995 Apr 1;18(4):517-22.

Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes care. 2005 May 1;28(5):1231-9.

Heinemann L et al. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes care. 2015 Apr 1;38(4):716-22.

Bankar SB et al. Glucose oxidase—an overview. Biotechnology advances. 2009 Jul 1;27(4):489-501.

Wilson R, Turner AP. Glucose oxidase: an ideal enzyme. Biosensors and Bioelectronics. 1992 Jan 1;7(3):165-85.

Jagathy K et al. Production, optimization, Characterization and Immobilization of Glucose oxidase from Aspergillus species. Research Journal of Pharmacy and Technology. 2017;10(6):1924-8.

Yu J et al. Advances in bioresponsive closed-loop drug delivery systems. International journal of pharmaceutics. 2018 Jun 15;544(2):350-7.

Kizaka‐Kondoh S, Konse‐Nagasawa H. Significance of nitroimidazole compounds and hypoxia‐inducible factor‐1 for imaging tumor hypoxia. Cancer science. 2009 Aug;100(8):1366-73.

Xu Y et al. Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates. Journal of biomedical optics. 2013 Jun;18(6):066009.

Scognamiglio V et al. D-galactose/D-glucose-binding Protein from Escherichia coli as Probe for a Non-consuming Glucose Implantable Fluorescence Biosensor. Sensors. 2007 Oct;7(10):2484-91.

Tolosa L, Rao G. The glucose binding protein as glucose sensor. InGlucose Sensing 2006 (pp. 323-331). Springer, Boston, MA.

Reeke GN et al. Structure and function of concanavalin A. InConcanavalin A. Springer, Boston, MA 1975 pp. 13-33.

Cummins BM et al. Optimization of a concanavalin A-based glucose sensor using fluorescence anisotropy. Analytical chemistry. 2013 Jun 4;85(11):5397-404.

Yin R et al. Glucose and pH dual-responsive concanavalin A based microhydrogels for insulin delivery. International journal of biological macromolecules. 2011 Dec 1;49(5):1137-42.

Miyata T et al. Preparation of reversibly glucose-responsive hydrogels by covalent immobilization of lectin in polymer networks having pendant glucose. Journal of Biomaterials Science, Polymer Edition. 2004 Jan 1;15(9):1085-98.

Obaidat AA, Park K. Characterization of protein release through glucose-sensitive hydrogel membranes. Biomaterials. 1997 Jun 1;18(11):801-6.

Sawant SV, Sankpal SV, Jadhav KR, Kadam VJ. Hydrogel as drug delivery system. Research Journal of Pharmacy and Technology. 2012;5(5):561-9.

Fang H et al. Progress in boronic acid-based fluorescent glucose sensors. Journal of Fluorescence. 2004 Sep 1;14(5):481-9.

Karnati VV et al. A glucose-selective fluorescence sensor based on boronicacid-diol recognition. Bioorganic & medicinal chemistry letters. 2002 Dec 2;12(23):3373-7.

What Is Excessive Blood Clotting (Hypercoagulation)? | American Heart Association [Internet]. [cited 2019 Oct 15]. Available from: https://www.heart.org/en/health-topics/venous-thromboembolism/what-is-excessive-blood-clotting-hypercoagulation

Penner JA. Hypercoagulation and thrombosis. The Medical clinics of North America. 1980 Jul;64(4):743-59.

Le Bonniec BF. Thrombin. InHandbook of Proteolytic Enzymes 2013 Jan 1 (pp. 2915-2932). Academic Press.

Alqatab AH, Hassan AH. Evaluation of some Coagulation Factors in Male rat with Induce Chronic Renal Failure (CRD). Research Journal of Pharmacy and Technology. 2019;12(4):1871-4.

Brinkhous KM et al. The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. American Journal of Physiology-Legacy Content. 1939 Mar 31;125(4):683-7.

Capila I, Linhardt RJ. Heparin–protein interactions. Angewandte Chemie International Edition. 2002 Feb 1;41(3):390-412.

Hirsh J. Heparin. New England Journal of Medicine. 1991 May 30;324(22):1565-74.

Hirsh J. Low molecular weight heparin. Thrombosis and haemostasis. 1993 Jan;69(01):204-7.

Freedman MD. Pharmacodynamics, clinical indications, and adverse effects of heparin. The Journal of Clinical Pharmacology. 1992 Jul;32(7):584-96.

Maitz MF et al. Bio-responsive polymer hydrogels homeostatically regulate blood coagulation. Nature communications. 2013 Jul 19;4(1):1-7.

Bhat R et al. Thrombin-responsive gated silica mesoporous nanoparticles as coagulation regulators. Langmuir. 2016 Feb 9;32(5):1195-200.

Zhang Y et al. Thrombin‐responsive transcutaneous patch for auto‐anticoagulant regulation. Advanced materials. 2017 Jan;29(4):1604043.

Yu J et al. Bioresponsive transcutaneous patches. Current opinion in biotechnology. 2017 Dec 1;48:28-32.

World Health Organisation. Global cancer data. Int Agency Res cancer [Internet]. 2018;(September):13–5. Available from: http://gco.iarc.fr/,

WHO Cancer Control Programme 2019 [Internet]. World Health Organization. 2019 [cited 2019 Jul 15]. Available from: https://www.who.int/cancer/en/

Hasan MK, Ghareeb MM, Mate BF, Aga QA. Clinical adverse effects of Chemotherapy protocolusing 6-Mercaptopurine in Iraqi patients with Acute Lymphocytic Leukemia during Maintenance Phase. Research Journal of Pharmacy and Technology. 2019 Dec 30;12(12):5757.

Nag MK et al. Lung Cancer Targeting: A Review. Research Journal of Pharmacy and Technology. 2013;6(11):1302-6.

Kalyankar TM et al. Application of Nanotechnology in Cancer Treatment. Research Journal of Pharmacy and Technology. 2012;5(9):1161-7.

Vaupel P et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer research. 1989 Dec 1;49(23):6449-65.

Maeda H et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of controlled release. 2000 Mar 1;65(1-2):271-84.

Fischer K et al. Inhibitory effect of tumor cell–derived lactic acid on human T cells. Blood. 2007 May 1;109(9):3812-9.

Warburg O et al. The metabolism of tumors in the body. The Journal of general physiology. 1927 Mar 7;8(6):519.

Das K, Mishra SC. Estimation of tumor characteristics in a breast tissue with known skin surface temperature. Journal of Thermal Biology. 2013 Aug 1;38(6):311-7.

Shimma S et al. MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis. Journal of Chromatography B. 2007 Aug 1;855(1):98-103.

Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. InSeminars in radiation oncology 2004 Jul 1 (Vol. 14, No. 3, pp. 198-206). WB Saunders.

You JO, Auguste DT. Feedback-regulated paclitaxel delivery based on poly (N, N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles. Biomaterials. 2008 Apr 1;29(12):1950-7.

Andualema B, Gessesse A. Microbial lipases and their industrial applications. Biotechnology. 2012 May 1;11(3):100-18.

Muthumari GM et al. Industrial Enzymes: Lipase Producing Microbes from Waste Volatile Substances. International Journal of Pharmaceutical Sciences and Research. 2016 May 1;7(5):2201.

Jaeger KE et al. Bacterial lipases. FEMS microbiology reviews. 1994 Sep 1;15(1):29-63.

Stehr F et al. Microbial lipases as virulence factors. Journal of molecular catalysis B: enzymatic. 2003 Jul 11;22(5-6):347-55.

Bharadwaj B, Gopinath P. Detection of Lipase and Lecithinase among Clinical isolates of Pseudomonas aeruginosa. Research Journal of Pharmacy and Technology. 2016;9(11):1909-12.

Singh AK, Mukhopadhyay M. Overview of fungal lipase: a review. Applied biochemistry and biotechnology. 2012 Jan 1;166(2):486-520.

Aspergillosis - Infections - MSD Manual Consumer Version [Internet]. [cited 2019 Oct 16]. Available from: https://www.msdmanuals.com/en-in/home/infections/fungal-infections/aspergillosis

Chen M et al. Pulmonary fungus ball caused by Penicillium capsulatum in a patient with type 2 diabetes: a case report. BMC infectious diseases. 2013 Dec 1;13(1):496.

Vanittanakom N et al. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clinical microbiology reviews. 2006 Jan 1;19(1):95-110.

Laxmaiah Manchikanti M et al. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain physician. 2010 Sep;13:401-35.

U.S. government considered using FENTANYL for executions while Trump fights opioid crisis | Daily Mail Online [Internet]. [cited 2019 Oct 16]. Available from: https://www.dailymail.co.uk/news/article-7460613/U-S-government-considered-using-FENTANYL-executions-Trump-fights-opioid-crisis.html

Chahl LA. Opioids - Mechanisms of action. Aust Prescr. 1996;19(3):63–5.

Pavithra D et al. A Comprehensive Review on Complications of Intravenous Drug Abuse. Research Journal of Pharmacy and Technology. 2017 May 28;10(5):1523-7.

The Rise of the U.S. Opioid Crisis - The Globalist [Internet]. [cited 2019 Oct 21]. Available from: https://www.theglobalist.com/the-rise-of-the-united-states-opioid-crisis/

Opioid Overdose Crisis | National Institute on Drug Abuse (NIDA) [Internet]. [cited 2019 Oct 21]. Available from: https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis

5 facts about the US opioid crisis, and signs it’s spreading | World Economic Forum [Internet]. [cited 2019 Oct 21]. Available from: https://www.weforum.org/agenda/2019/07/us-opioid-crisis-health-healthcare/

Refbacks

  • There are currently no refbacks.


Bookmark and Share